BioCentury
ARTICLE | Company News

Allergan sheds $4.5B in market cap on 4Q18 earnings

January 30, 2019 12:43 AM UTC

Allergan plc (NYSE:AGN) lost $13.57 to $145.12 on Tuesday after it reported a $4.3 billion net loss in 4Q18 and presented 1Q19 guidance well below the Street’s consensus. The stock move translates to a loss in market cap over $4.5 billion.

Allergan’s 4Q18 GAAP loss per share of $12.83 is a stark reversal to the $9.97 GAAP EPS and $3.1 billion income gain it recorded in 4Q17. The loss includes a GAAP impairment charge of $5.4 billion, including a $1.6 billion intangible asset impairment related to Kybella deoxycholic acid and a $3.5 billion goodwill impairment due to the enterprise value of its U.S. General Medicine segment falling below book value...

BCIQ Company Profiles

Allergan plc